Probi AB   Report issue

For profit Phase 2
Founded: Lund Sweden (1991)
Status: No NME R&D (1991)

Organization Overview

First Clinical Trial
2010
NCT01989702
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Probi AB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Diseases, Metabolic (Phase 2)

Common Cold (Phase 2)

Communicable Diseases (Phase 2)

Diarrhea (Phase 2)

Infections (Phase 2)

Inflammation (Phase 1)

Irritable Bowel Syndrome (Phase 2)

Respiratory Tract Infections (Phase 2)

Syndrome (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 15
  • # of Trial APIs: 6